Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Gulam Manji, MD, PhD
Email
gam2140@cumc.columbia.edu

Gulam Manji, M.D., Ph.D. is an Assistant Professor of Medicine at Columbia University Medical Center. Dr. Manji received his M.D. degree from Ross University School of Medicine in 2009 and completed his residency in internal medicine at Albany Medical College. He then completed his fellowship in Hematology/Oncology at NewYork-Presbyterian/Columbia, where his clinical focus was on the treatment of gastrointestinal malignancies, melanoma, and sarcoma under the mentorship of Dr. Gary Schwartz, Chief of Hematology and Oncology.

Dr. Manji conducts translational research with the overall goal to developing new treatments for cancer. His focus is in gastrointestinal malignancies, particularly pancreas adenocarcinoma, on which he is conducting preclinical combination immunotherapy studies on genetically engineered mice with pancreas cancer in the Olive laboratory at the Herbert Irving Comprehensive Cancer Center. The combination immunotherapy preclinical proposal received the Young Investigator Award from the American Society of Clinical Oncology-2015. The goal of these preclinical studies is to bring promising new therapies to the clinic in an early phase clinical trials Dr. Manji's research career in identifying new genes and their implication in disease has led to numerous key publications and an issued patent.

Dr. Manji cares for patients with gastrointestinal malignancies, with a particular focus on pancreatic and liver cancers, and sarcomas. He is the principal investigator of an investigator-initiated multicenter clinical trial that he wrote with Dr. Gary Schwartz in sarcoma and malignant peripheral nerve sheath tumors and is responsible for clinical trials conducted in liver, bile duct, gallbladder, and pancreas cancers at Columbia University Medical Center.


Clinical Studies Managed By Dr. Manji:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study patients with metastatic or recurrent Gastric or Gastroesophageal Junction Adencarcinoma using study drug MEDI4736MedImmuneAAAO8258
Details[CLOSED] A study for patients with biliary or gallbladder cancer using study drug DKN-01HealthCare PharmaceuticalsAAAO7003
Details[CLOSED] A Study for patients with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma using study drug pembrolizumabMerckAAAO8259
DetailsA study for patients with malignant peripheral nerve sheath tumors using study drugs PLX3397 and SirolimusPlexxikonAAAO6059
Details[CLOSED] A study for patients with metastatic Pancreatic Cancer using study drug MM-141 plus NabPaclitaxel and GemcitabineMerrimack PharmaceuticalsAAAQ0008
Details[CLOSED] A study for patients with liver cancer using study drug RO7070179Hoffmann-La RocheAAAQ4550
DetailsA Study for Patients with Solid Tumors Using Study Drug AtezolizumabGenentech, Inc.AAAQ7567
Details[CLOSED] A study for patients with advanced hepatocellular carcinoma using study drug pembrolizumabMerck Sharp & Dohme Corp.AAAQ8401
DetailsA study for patients with gastric cancer using study drug PembrolizumabMerck Sharp & Dohme Corp.AAAQ9871
Details[CLOSED] A study for patients with locally advanced or metastatic solid tumors using study drug RO6958688Hoffmann-La Roche LtdAAAR1902
Details[CLOSED] A study for patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors using study drug RO6958688Hoffmann-La RocheAAAR2410
DetailsStudy of Multiple Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)F. Hoffmann - La Roche LtdAAAR2578
DetailsStudy of Treatment Combinations in Patients with Gastric or Gastroesophageal Junction Cancer (Morpheus-Gastric Cancer)F. Hoffmann- La Roche Ltd.AAAR4882
DetailsStudy of Cibisatamab in Combination with Atezolizumab in Patients with Colorectal CancerF. HoffmannLa RocheAAAS1555
DetailsFeasibility, Safety, and Activity Study of BPX-601 in Subjects With Previously Treated Advanced Solid TumorsBellicum Pharmaceuticals, Inc.AAAR9974
DetailsFirst-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid TumorsGlaxoSmithKlineAAAS1446